Premia Global Advisors’s Novartis NVS Stock Holding History

Premia Global Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,272	Closed	-$367K	–	278
2019 Q1	$367K	Buy	+4,272	New	+$343K	0.37%	43
2018 Q2	–	Sell	-3,683	Closed	-$266K	–	319
2018 Q1	$266K	Buy	3,683 +153	+4%	+$11.6K	0.23%	78
2017 Q4	$264K	Buy	+3,530	New	+$266K	0.26%	81

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Premia Global Advisors's NVS Position: Q2 2019 in Review

Premia Global Advisors sold out of Novartis (NVS) in Q2 2019, closing a stake of 4,272 shares — an estimated $367K sold.

Premia Global Advisors first reported a position in NVS in Q4 2017 and held it in 3 quarters. The position peaked at $367K in Q1 2019. 1,094 funds tracked by Wall St. Rank hold NVS as of Q2 2019.

Premia Global Advisors reported no remaining Novartis position as of Q2 2019 after selling out during the quarter.
Premia Global Advisors sold 4,272 Novartis shares in Q2 2019, an estimated $367K.
Premia Global Advisors first reported a position in Novartis in Q4 2017 and held it in 3 quarters.
Premia Global Advisors's Novartis position peaked at $367K in Q1 2019.
1,094 funds tracked by Wall St. Rank held Novartis as of Q2 2019.

Based on Premia Global Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.